Do cerebral microbleeds in asymptomatic individuals reflect early CAA? The Early Detection of Angiopathy (EDAN) Study

• Conditions: 10047075; cerebral amyloid angiopathy; protein accumulation

• Registration Number: NL-OMON39566
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

1) One or more strictly lobar CMB on previously performed 3D T2*-weighted GRE MRI
2) Ability and willingness to provide written informed consent
3) Age >=60. There is no upper age limit or restriction on race or gender for study participation.

Exclusion Criteria

1) Other definite cause of microbleeds of hemorrhage. Exclusion causes are excessive anticoagulation (INR >3.0), antecedent head trauma or ischemic stroke, CNS tumor, vascular malformation, vasculitis, and blood dyscrasia
2) History of symptomatic hemorrhagic stroke
3) Microbleeds outside lobar or cerebellar brain regions (e.g. basal ganglia, thalamus, brainstem) demonstrated by neuroimaging. The presence of additional cerebellar CMBs is not an exclusion criterium, as CAA can affect the cerebellum.
4) Dementia
5) Contra-indication to MRI (e.g. cranial metallic implant, cardiac pacemaker, severe claustrophobia)
6) Specific contraindications to fMRI, i.e.:
a. History of diabetes, ischemic stroke, transient ischemic attack, carotid/intracranial artery stenosis
b. Current tobacco use
c. Change in antihypertensive medication within the previous three months.
d. Seizure within prior year
e. Noncorrectable visual impairment

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified